Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that new data from a phase 3 trial of the multi-center, randomized ...
The MyProstateScore 2.0 urine test captures 17 biomarkers of clinically significant prostate cancer, independent of PSA. A positive result can rule in and a negative result can rule out the need for ...
Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was associated with measurable molecular improvement in prostate health within 30 days, ...
The study's testing accurately identified prostate cancer 91% of the time and accurately ruled out men without prostate cancer 84% of the time. A urine-based biomarker panel may be a promising, ...
Prostate cancer is the second leading cause of cancer death in men in the U.S., with an expected 288,000 cases and 34,700 deaths expected in 2023, per the American Cancer Society. As artificial ...
Prostate health remains a crucial topic that many men avoid discussing, even with close family members. Early screenings can make a significant difference in detecting issues before they become severe ...
A technique to improve the precision of prostate cancer surgery means that almost twice as many men preserve their erectile function compared to those undergoing standard surgery, according to results ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results